Mr. Song Qing joined the Group in August 2018 as an executive Director and the vice chairman, and has been re-designated as the Chairman of the Board of the Group since April 2021. Mr. Song has extensive experiences in corporate management, and has over 30 years of experience and sophisticated background in the pharmaceutical industry. Mr. Song is currently the chairman of China Resources Healthcare Group Limited (which is principally engaged in investments in healthcare sector and operation and management of medical institutes). Mr. Song was the director of China Resources Pharmaceutical Group Limited (which is listed on the Main Board of the Stock Exchange; stock code: 3320) from May 2016 to August 2018, and also its president from June 2017 to August 2018. Mr. Song was the director of China Resources Sanjiu Medical & Pharmaceutical Co Ltd (which is listed on Shenzhen Stock Exchange; stock code: 000999) up to August 2018, and its chairman of the board from June 2017 to August 2018. He also served as an inspection pharmacist of quality inspection department, a pharmacist in charge and the director of production department, the director of the enterprise management department and an assistant to president of Shenzhen South Pharmaceutical Factory. Mr. Song served as an assistant general manager, the director of technology center, the director of medical & pharmaceutical department of Sanjiu Enterprise.

Mr. Yu was appointed as Executive  Director and President of China Resources Medical Holdings Company Limited. Mr. Yu is also the Vice Chairman and General Manager of CR Healthcare and Chairman and General Manager of China Resources Liaoning Health Industry Investment Group co., LTD. He was once a vice mayor and a member of the party committee of the people's government of Benxi city, Liaoning province. He also worked in science and technology department of Liaoning provincial. With a doctor's degree in pharmaceutical management of Shenyang pharmaceutical university, he officially joined CR in 2019.

Mr. Shan was appointed as the vice President of China Resources Medical Holdings Company Limited. Mr Shan is also the Vice General Manager of CR Healthcare. He once served as Deputy General Manager of Phoenix Healthcare Group and worked for Shenyang Northeast General Pharmaceutical Factory, Northeast Pharmaceutical Group Co., Ltd., China Food and Drug Administration, and the Drug Safety Assessment Center of China Food and Drug Administration. With a master’s degree in Business Administration at Renmin University of China and a bachelor’s degree in Chemistry at Wuhan University, he officially joined CR in 2016.

Mrs. Yang was appointed as the executive director and Chief Financial Officer of China Resources Medical Holdings Limited. Mrs. Yang is also the financial director of CR Healthcare. She once served as general manager , Senior Vice General Manager of the Finance Department and deputy General Manager (chair) of Audit Department of CR Gas, manager of Ernst & Young Shenzhen Branch Office, etc. . Mrs. Yang holds a bachelor's degree in management from Northwestern University and a Chinese. She is also a Chinese Certified Public Accountant . She joined CR in 2009.

Mrs Ge was appointed as a non-executive director and member of the Remuneration Committee of the company on 14 September, 2023. She is currently an external director of CR Healthcare. She had served as deputy general manager and Chief Information Officer of China Resources Pharmaceutical Group Co. , Ltd. She was also an assistant to General Manager of Beijing Pharmaceutical Co. , Ltd. . Mrs Ge holds a Master of Business Administration degree from Tsinghua University and a bachelor's degree in computer science from Beijing Jiaotong University. She joined CR in 2012.

Mr. Hu joined the group in August 2018 and was appointed as an independent non-executive director and chairman. He resigned as chairman in April 2021. Mr. Hu is a leader in the medical industry, with rich experience in the management of the medical system. Mr. Hu joined board of the Hospital Authority of Hong Kong in 1999 and served as chairman from 2004 to 2013. He is the longest-serving HA chairman in by far. During his tenure, he led the HA team in managing all public hospitals and clinics in Hong Kong, implementing the Public Health Policy of the HKSAR Government, and actively promoting a number of public-private healthcare co-operation programmes. Mr. Hu is currently the principal adviser to the State Administration of Traditional Chinese Medicine and a member of the Expert Advisory Committee on the Reform and development of Chinese medicine. He was also a member of the advisory committee of Experts on Healthcare reform in the People's Republic of China and a consultant to the advisory committee of Experts on public policy of the National Health and Family Planning Commission of the People's Republic of China. His hold the office for Standing Committee of the 12th and 13th National Committee of the People's Republic of China, member of the Chief Executive's Advisory Panel on innovation and strategic development and member of the task force on land supply. He has been appointed a Justice of the peace and an Gold Bauhinia Star by the HKSAR Government. Mr. Hu was also chairman of the Hong Kong General Chamber of Commerce from 2010 to 2012 and is currently a member of the Advisory Council of the chamber. Mr. Hu was a partner of Ernst & Young from 1985 to 2015.He was the chairman of Ernst & Young Eastern from 2000 to 2005.

He is currently the principal adviser of Mitsubishi UFJ Bank in Tokyo, chairman of the China Scholarship Foundation at Oxford University, Professor Emeritus of Faculty of Medicine, the Chinese University of Hong Kong and Peking Union Medical College Hospital. He is the Honorary Fellow of the Hong Kong School of Social Medicine. Mr. Hu also serves as a director of a number of companies listed on the main board of the stock exchange,  such as Sing Tao News Corporation (Stock Code: 1105) , Electric Power Industry Co. , Ltd. (stock code: 006) , Guangdong Investment (stock code: 270) , China Taiping Insurance Holdings (stock code: 966) , Cornerstone Pharmaceutical Co. , Ltd. (stock code: 2616) and Hangzhou Qiming Medical Device Co. , Ltd. (stock code: 2500)  and etc.. In 2020, he also took up the position of independent non-executive director of Ogilvy Vision Biology (stock code: 1477) . Mr. Yu took up the position of non-executive director and chairman of Clear Healthcare Group Holdings Limited (stock code: 1406) in 2021 , which went public in early 2022. He is a former executive director of Sincere Watch (Hong Kong) Limited (stock code: 444) .  He was also an independent non-executive director of Agricultural Bank of China Limited (stock code: 1288) from 2009 to 2015 and a director of Fidelity Funds from 2011 to 2014. Mr. Hu is a senior member of the Hong Kong Institute of Certified Public Accountants and Institute of Chartered Accountants in England and Wales. He is also the honorary Chairman of the Hong Kong branch of the Australian Institute of Management Accountants.

Mr. Hu was appointed as an independent non-executive director of eight listed companies and a non-executive director of a listed company. He confirmed that he would devote sufficient time to serving as an independent non-executive director of the company for the following reasons. First, Mr. Hu is not a full-time employee of the companies, nor is he involved in the daily operation or management of the companies. As a result, Mr. Hu has no executive and management responsibilities in respect of these companies. Second, He is not the chief executive officer or a full-time executive director of any listed company. Third, by virtue of his background and experience, Mr. Hu is fully aware of the responsibilities and expected time as the independent non-executive directors. He has a good understanding of his responsibilities as an independent director in a number of listed companies and the estimated time required to participate in the affairs of each listed company. It has no difficulty in investing and managing its time in a number of companies and he is confident that he is able to fulfil its responsibilities towards the companies with his experience in a number of positions. Fourth, Mr. Hu's position with the group is non-executive and he will not be involved in the daily management of the group's operations. Therefore, as an independent non-executive director of the company, full-time participation is not required.

For the above reasons, the directors consider that Mr. Hu's current multiple positions will not result in nonsufficient time to serve as an independent non-executive director of the company or unable to properly discharge his fiduciary duty as a director of the company.

Mr. Kuang joined the group in September 2013 and was appointed as an independent non-executive director and chairman of the Audit Committee. He was appointed as a member of the Nominating Committee on 23 March, 2018. Mr. Kuang was previously the chief executive officer of Pok Oi Hospital, a well-known non-profit hospital in Hong Kong. As president, Mr. Kuang has been providing corporate governance and management support to the board of directors for the past 10 years to develop, manage and supervise the unit under Pok Oi Hospital. Mr. Kuang joined Pok Oi Hospital in 2003 as an internal audit manager. He is currently a director of Yuen Long District Health City Limited, a nonprofit organization in response to the government's efforts to promote community health messages to the public. Prior to joining Pok Oi Hospital, Mr. Kuang was the principal auditor of the Audit Commission of the Hong Kong Special Administrative Region Government. Mr. Kuang has served in the Audit Commission of the Hong Kong Government since 1980. He became a member of the Hong Kong Institute of Certified Public Accountants (HKICPA) in 1982.

Mr. Fu was  appointed as an independent non-executive director of the company in February, 2023. He is also an independent non-executive director of China Resources Pharmaceutical Group Limited (stock code: 3320) , Guotai Junan Securities International Holdings Limited (Stock Code: 1788) , Postal Savings Bank of China International Limited (stock code: 1658) and Cofco Ka Hong Foods Limited (stock code: 1610) . Mr. Fu was an independent non-executive director of the Beijing Enterprises Stock Exchange (listed on the Stock Exchange, stock code: 0392) from July 2008 to June 2017. He was an independent non-executive director of the CPMC Holdings Limited Stock Exchange (listed on the Stock Exchange, stock code: 0906) From June 2008 to July 2019. Mr. Fu has more than 30 years of experience in investment, finance, legal and business management. Mr. Fu holds a Master of Laws degree and a Doctor of Philosophy degree in law from the University of London.

Mr. Zhou joined the group on 14 September, 2023. He was appointed as an independent non-executive director and member of the Audit Committee.  Mr. Zhou is the founder of Deep Blue Ridge Capital, which is a Hong kong-based multi-strategy investment firm. Mr. Zhou has 20 years of experience in Global M & A and capital market operations. Prior to setting up DBR Capital, Mr. Zhou worked for Deutsche Bank (Hong Kong) and Credit Suisse (New York). He worked with the world's top institutions and corporate clients to complete a number of cross-industry, cross-product transactions. Mr. Zhou began his career at the Bank of China. Mr. Zhou holds a Master of Business Administration degree from Columbia University in New York.